Additionally, targeting XIAP together with BCL‐2 was recently suggested as promising treatment for aggressive AML subtypes, where certain mutations, karyotypes and TP53 transcriptional activity correlated with response (Hashimoto et al, 2021). Here, TP53 is linked to acute myeloid leukemia.